FDA grants a fourth bispecific antibody, linvoseltamab, accelerated approval for relapsed or refractory multiple myeloma: The approval of linvoseltamab likely also benefits from the fact that "over time we have learned how to give these drugs in a safer way."-Ajay K. Nooka, MD, MPH.